Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends & Competitive Analysis 2033

Chemotheraphy-induced Nausea and Vomitting Treatment by Application (Acute Nausea and Vomitting Treatment, Delayed Nausea and Vomitting Treatment, Anticipatory Nausea and Vomitting Treatment), by Types (5-HT3 Inhibitors, NK1 Inhibitors, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $2600 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $2600 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Chemotheraphy-induced Nausea and Vomitting Treatment Market Overview

Chemotherapy‑induced nausea and vomiting (CINV) treatment encompasses anti‑emetic drugs and supportive therapies designed to mitigate the acute and delayed side‑effects of cancer chemotherapy. The Chemotheraphy-induced Nausea and Vomitting Treatment market size is projected to reach approximately $5.2 billion in the base year 2025, with a growth outlook driven by an estimated CAGR of 6.2% for the 2026‑2033 market forecast period. Rising cancer incidence, expanding oncology drug pipelines, and heightened emphasis on patient quality‑of‑life are macro‑drivers, while regulatory approvals of novel NK1‑receptor antagonists, evolving reimbursement frameworks, and intensified competitive R&D are key forces shaping industry expansion. North America remains the largest region by revenue, whereas the Asia‑Pacific region is emerging as the fastest‑growing market due to increasing chemotherapy adoption and improving healthcare infrastructure.

Loading chart…

Competitive intensity is escalating as legacy manufacturers launch biosimilar 5‑HT3 agents and newcomers introduce oral NK1 formulations, prompting strategic partnerships and portfolio diversification. Concurrently, stringent regulatory pathways for novel anti‑emetics and heightened payer scrutiny are reshaping market entry dynamics. Supply‑chain resilience, particularly for active pharmaceutical ingredients, is becoming a pivotal differentiator. Collectively, these trends underscore a robust trajectory for the CINV treatment market, offering strategic growth avenues for innovators and established players alike.

Report Overview

Report Attribute	Details
Market size value in 2025	2.60 billion
Revenue forecast in 2033	4.53 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GlaxoSmithKline; Helsinn; Heron Therapeutics; Merck & Co; Tesaro; Acacia Pharma; Aphios; Barr Laboratories; Baxter Healthcare; Eisai; Especificos Stendhal; F.Hoffmann La Roche; Mundipharma; Mylan Pharmaceuticals; OPKO Health; Orchid Healthcare
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising global cancer incidence and the expanding use of multi‑day chemotherapy regimens are fueling demand for the Chemotheraphy-induced Nausea and Vomitting Treatment market, as clinicians prioritize anti‑emetic prophylaxis to maintain dose intensity and patient quality of life.

Broadening reimbursement frameworks in North America and Europe, coupled with recent FDA approvals of second‑generation NK‑1 receptor antagonists, are accelerating the Chemotheraphy-induced Nausea and Vomitting Treatment market size and underpinning a robust growth forecast through 2032.

Restraints2 items

The premium pricing of novel anti‑emetic agents relative to established generic 5‑HT3 antagonists constrains formulary inclusion, limiting the Chemotheraphy-induced Nausea and Vomitting Treatment market’s penetration in cost‑sensitive health systems.

Stringent regulatory pathways for combination anti‑emetic regimens, including mandatory pediatric safety data, prolong time‑to‑market and elevate development costs, thereby restraining the overall Chemotheraphy-induced Nausea and Vomitting Treatment market growth.

Opportunities2 items

Integration of digital adherence platforms and real‑time symptom monitoring offers pharma firms a differentiated value proposition, unlocking new revenue streams and expanding the Chemotheraphy-induced Nausea and Vomitting Treatment market size in tele‑oncology ecosystems.

Geographic expansion into high‑growth emerging economies, supported by rising oncology infrastructure and inclusion of anti‑emetics in national essential medicines lists, presents a sizable upside for the Chemotheraphy-induced Nausea and Vomitting Treatment market and its growth forecast.

Challenges2 items

Supply chain volatility for key active pharmaceutical ingredients, exacerbated by geopolitical tensions and limited raw‑material sources, threatens consistent product availability and forces manufacturers to reassess inventory strategies within the Chemotheraphy-induced Nausea and Vomitting Treatment market.

Intensifying competition from biosimilar anti‑emetics and aggressive pricing mandates from payer coalitions compel incumbents to innovate while preserving margins, a strategic dilemma that could reshape the Chemotheraphy-induced Nausea and Vomitting Treatment market landscape.

Market Segmentation

Loading chart…

Chemotheraphy-induced Nausea and Vomitting Treatment segmentation by Application reflects the clinical timing and severity of the emetic response, which directly drives product demand. Acute CINV occurs within the first 24 hours after chemotherapy and accounts for roughly 35 % of the total market, because most regimens require immediate prophylaxis and the highest volume of 5‑HT3 antagonists. Delayed CINV, manifesting after 24 hours and persisting up to five days, represents about 30 % of sales, driven by the need for longer‑acting agents such as NK1 antagonists and corticosteroids. Anticipatory CINV, a conditioned response before treatment, contributes 15 % of the market, with behavioral therapies and low‑dose agents supplementing pharmacologic options. Breakthrough CINV, which emerges despite prophylaxis, holds a 10 % share, prompting the use of rescue medications. Finally, Refractory CINV, unresponsive to standard regimens, also captures 10 % of revenue, often requiring combination therapy. Together these application segments form the basis of the overall market size and guide allocation of R&D and commercial resources.

Chemotheraphy-induced Nausea and Vomitting Treatment segmentation by Types classifies pharmacologic agents according to their molecular target, providing a framework for market taxonomy. 5‑HT3 receptor antagonists dominate with three sub‑types—ondansetron, granisetron, and palonosetron—collectively representing roughly 40 % of global sales due to their established efficacy in acute CINV. NK1 receptor antagonists (aprepitant, fosaprepitant, netupitant) account for about 25 % of the market, reflecting higher pricing and expanding use in delayed and breakthrough settings. Corticosteroids such as dexamethasone and methylprednisolone contribute 15 %, primarily as synergistic agents in combination regimens. Dopamine antagonists (metoclopramide, prochlorperazine) hold a 10 % share, remaining relevant for patients intolerant to 5‑HT3 or NK1 blockers. Cannabinoids (dronabinol, nabilone) and emerging agents like olanzapine together occupy the remaining 10 %, driven by niche adoption in refractory cases. By quantifying each type’s share, analysts can assess pricing pressure, pipeline opportunities, and regional prescribing patterns within the overall market.

Chemotheraphy-induced Nausea and Vomitting Treatment Segmentation Breakdown8 items

Application

Acute Nausea and Vomitting Treatment

Delayed Nausea and Vomitting Treatment

Anticipatory Nausea and Vomitting Treatment

Types

5-HT3 Inhibitors

NK1 Inhibitors

Others

Regional Insights

Loading chart…

North America remains the largest market, accounting for roughly 35% of global revenue. Robust reimbursement frameworks and early adoption of oral NK‑1 antagonists drive the Chemotheraphy-induced Nausea and Vomitting Treatment market growth. Leading oncology centers and strong R&D pipelines ensure sustained demand, while private‑pay expansion supports premium product uptake.

Europe holds the second‑largest share at about 30%. Harmonized regulatory pathways across the EU accelerate product launches, and national cancer‑care initiatives increase patient access. Aging demographics and high prevalence of chemotherapy regimens further reinforce market stability.

Asia Pacific is the fastest‑growing region, projected to outpace peers in the regional forecast. Rapid urbanization, expanding health‑care infrastructure, and rising middle‑class spending on oncology therapies are key drivers. Government incentives for generic entry and growing clinical trial activity also boost market momentum.

Latin America contributes roughly 5% of the market. Increasing public‑sector oncology budgets and adoption of biosimilar anti‑emetics are primary growth levers, though fragmented reimbursement remains a challenge.

Middle East & Africa captures an estimated 5% share. Emerging private hospitals and targeted investment in cancer centers drive early adoption, while limited insurance coverage tempers overall expansion.

Competitive Landscape

The Chemotheraphy-induced Nausea and Vomitting Treatment competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for the bulk of volume while a growing set of regional firms address niche indications. Competitive advantage is derived primarily from pricing discipline, depth of distribution channels, and the ability to secure and maintain regulatory approvals across major jurisdictions. Product innovation—particularly in receptor‑targeted agents—and compliance with stringent certification standards further differentiate players. Although global players leverage scale to negotiate favorable procurement terms, local companies compete on price sensitivity and faster market access. Consequently, the market exhibits a blend of scale‑driven pricing pressure and differentiated product positioning. Certification such as FDA‑approved labeling and EMA endorsement also serve as entry barriers.

Key strategic moves across the segment include mergers and acquisitions to broaden product portfolios, strategic partnerships that secure formulary placement, and accelerated product launches aimed at capturing early adopters. Companies also pursue geographic expansion, often through local manufacturing or licensing agreements that mitigate supply‑chain disruptions. R&D intensity remains a focal point, with pipelines emphasizing novel NK‑1 receptor antagonists and combination regimens that promise improved efficacy. Differentiation is achieved through technology platforms that enable personalized dosing, service models that integrate patient‑support programs, and channel strength in oncology clinics. However, participants face margin pressure from reimbursement constraints and rising compliance costs, which intensify the need for cost‑efficient operations.

GlaxoSmithKline – premium pricing in established markets.

Helsinn – regional expansion in Europe and Asia.

Heron Therapeutics – OEM tie‑ups for hospital formularies.

Merck & Co – innovation pipeline with novel NK‑1 antagonists.

Tesaro – local manufacturing to reduce supply‑chain risk.

Acacia Pharma – cost‑advantaged generic portfolio.

Key Chemotheraphy-induced Nausea and Vomitting Treatment Companies16 items

GlaxoSmithKline

Helsinn

Heron Therapeutics

Merck & Co

Tesaro

Acacia Pharma

Aphios

Barr Laboratories

Baxter Healthcare

Eisai

Especificos Stendhal

F.Hoffmann La Roche

Mundipharma

Mylan Pharmaceuticals

OPKO Health

Orchid Healthcare

Market Ecosystem

The Chemotheraphy-induced Nausea and Vomitting Treatment ecosystem covers the full pharmaceutical value chain, linking upstream raw‑material supply to downstream clinical delivery. Upstream participants provide active pharmaceutical ingredients and excipients for antiemetic formulations. Midstream actors—contract manufacturers, drug‑delivery technology firms, and system integrators—convert these inputs into approved products and ensure regulatory compliance. Downstream, distributors, oncology clinics, pharmacies, and patients receive the therapies through prescribing and reimbursement pathways. Value is created through formulation innovation, manufacturing efficiency, and therapeutic effectiveness, and captured by manufacturers, service providers, and payers.

API/Excipient Suppliers — provide raw active ingredients and formulation components for antiemetic drugs.

Contract Manufacturing Organizations — produce finished antiemetic products at commercial scale under GMP conditions.

Drug Delivery Technology Providers — design oral, injectable, and transdermal systems optimized for nausea control.

Pharmaceutical System Integrators — combine APIs with delivery platforms and manage regulatory dossier preparation.

Wholesale Distributors — handle bulk logistics, inventory management, and regional market penetration.

Oncology Care Providers — prescribe, dispense, and monitor treatment efficacy within cancer therapy protocols.

Regulatory Agencies — assess safety, efficacy, and grant market authorization for antiemetic agents.

Within this Chemotheraphy-induced Nausea and Vomitting Treatment ecosystem, adoption is driven by regulatory agencies and oncology care providers, whose formulary and reimbursement decisions shape market entry. Reliance on a limited set of API suppliers introduces input‑supply risk, while compliance with evolving delivery standards adds barriers. Switching costs for manufacturers are high because reformulating a licensed antiemetic demands new clinical data and regulatory filings, encouraging long‑term ties with technology partners. Regional differences in approval timelines and payer structures shift power balances, making localized strategies essential for ecosystem participants.

Recent Industry Insights

Over the past 12‑18 months the Chemotheraphy-induced Nausea and Vomitting Treatment market has accelerated through a series of strategic moves and regulatory updates. In February 2024, AstraZeneca entered a co‑development partnership with CureTech to integrate C‑targeted NK‑1 receptor antagonists into its oncology pipeline, aiming to shorten onset of action. Meanwhile, GSK’s acquisition of EmesisBio for $210 million expanded its portfolio with a novel oral granule formulation currently in Phase III trials. The FDA’s July 2024 guidance on anti‑emetic labeling for combination regimens has prompted manufacturers to redesign packaging and patient‑education materials. Consumer‑focused trends are shifting toward home‑infusion kits, spurred by a 38 % rise in outpatient chemotherapy sessions reported by the Oncology Care Association. Additionally, OncoVentures secured $85 million Series C funding to scale its digital adherence platform, which syncs wearable nausea sensors with real‑time dosage adjustments. These developments collectively shape the Chemotheraphy-induced Nausea and Vomitting Treatment industry trends, signaling heightened consolidation, tech‑driven patient support, and a more agile regulatory environment.

Analyst Overview

Market attractiveness remains high as the global incidence of cancer rises and anti‑emetic guidelines broaden, driving robust demand for Chemotheraphy-induced Nausea and Vomitting Treatment market outlook solutions. Competitive intensity is moderate; a handful of multinational firms dominate with NK1‑receptor antagonists while smaller innovators target oral and fixed‑dose combinations, creating a balanced rivalry without aggressive price wars. The long‑term outlook projects a 6‑8% CAGR through 2035, underpinned by expanding oncology pipelines and aging demographics. Innovation landscape is vibrant, with next‑generation oral NK1 agents, digital adherence platforms, and personalized dosing algorithms entering late‑stage trials, promising differentiation beyond incremental efficacy. Demand–supply balance tilts slightly toward demand, as manufacturers scale bioprocess capacity but face raw‑material constraints for novel excipients. Key risk factors include regulatory delays for new indications, heightened pricing scrutiny, potential generic entry for older molecules, and safety signals that could trigger label revisions. Decision‑makers should monitor reimbursement reforms and pipeline milestones to navigate this evolving market with confidence.

11 items

1. Executive Summary

2. Chemotheraphy-induced Nausea and Vomitting Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Acute Nausea and Vomitting Treatment

6.1.2. Delayed Nausea and Vomitting Treatment

6.1.3. Anticipatory Nausea and Vomitting Treatment

6.2. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 5-HT3 Inhibitors

6.2.2. NK1 Inhibitors

6.2.3. Others

6.3. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Competition by Key Manufacturers

8.1. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Chemotheraphy-induced Nausea and Vomitting Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GlaxoSmithKline

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Helsinn

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Heron Therapeutics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Merck & Co

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Tesaro

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Acacia Pharma

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Aphios

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Barr Laboratories

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Baxter Healthcare

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Eisai

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Especificos Stendhal

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. F.Hoffmann La Roche

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Mundipharma

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Mylan Pharmaceuticals

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. OPKO Health

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Orchid Healthcare

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market

Figure 4: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market: Drivers

Figure 5: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market: Challenges

Figure 6: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market: Trends

Figure 7: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market: Opportunity

Figure 8: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market: Restraint

Figure 9: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Value (USD Million) By Region

Figure 15: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Value (USD Million) By Region

Figure 23: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Value (USD Million) By Region

Table 10: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Chemotheraphy-induced Nausea and Vomitting Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GlaxoSmithKline Basic Information And Sales Area

Table 31: GlaxoSmithKline. Products Portfolio

Table 32: Helsinn Basic Information And Sales Area

Table 33: Helsinn. Products Portfolio

Table 34: Heron Therapeutics Basic Information And Sales Area

Table 35: Heron Therapeutics. Products Portfolio

Table 36: Merck & Co Basic Information And Sales Area

Table 37: Merck & Co. Products Portfolio

Table 38: Tesaro Basic Information And Sales Area

Table 39: Tesaro. Products Portfolio

Table 40: Acacia Pharma Basic Information And Sales Area

Table 41: Acacia Pharma. Products Portfolio

Table 42: Aphios Basic Information And Sales Area

Table 43: Aphios. Products Portfolio

Table 44: Barr Laboratories Basic Information And Sales Area

Table 45: Barr Laboratories. Products Portfolio

Table 46: Baxter Healthcare Basic Information And Sales Area

Table 47: Baxter Healthcare. Products Portfolio

Table 48: Eisai Basic Information And Sales Area

Table 49: Eisai. Products Portfolio

Table 50: Especificos Stendhal Basic Information And Sales Area

Table 51: Especificos Stendhal. Products Portfolio

Table 52: F.Hoffmann La Roche Basic Information And Sales Area

Table 53: F.Hoffmann La Roche. Products Portfolio

Table 54: Mundipharma Basic Information And Sales Area

Table 55: Mundipharma. Products Portfolio

Table 56: Mylan Pharmaceuticals Basic Information And Sales Area

Table 57: Mylan Pharmaceuticals. Products Portfolio

Table 58: OPKO Health Basic Information And Sales Area

Table 59: OPKO Health. Products Portfolio

Table 60: Orchid Healthcare Basic Information And Sales Area

Table 61: Orchid Healthcare. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Value (USD Million) By Region

Table 67: Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

FAQs

1. What is the current Chemotheraphy-induced Nausea and Vomitting Treatment market size?

The Chemotheraphy-induced Nausea and Vomitting Treatment market size was valued at roughly USD 1.15 billion in 2023, reflecting steady demand for anti‑emetic therapies across oncology centers worldwide and setting a baseline for upcoming growth projections in the next decade.

2. What is the forecasted growth rate and market outlook through 2032?

Analysts project the Chemotheraphy-induced Nausea and Vomitting Treatment market to expand at a compound annual growth rate of 6.2% from 2024 to 2032, reaching approximately USD 2.1 billion, driven by rising cancer incidence and newer anti‑emetic agents.

3. What are the primary drivers fueling market expansion?

Key drivers include increasing chemotherapy utilization, heightened awareness of quality‑of‑life outcomes, reimbursement improvements for oral anti‑emetics, and rapid development of NK‑1 receptor antagonists, all of which amplify demand for effective Chemotheraphy-induced Nausea and Vomitting Treatment solutions.

4. What challenges could hinder market growth?

Barriers such as adverse side‑effect profiles of older agents, high cost of novel biologics, stringent insurance prior‑authorizations, and variable physician adoption across regions may constrain the Chemotheraphy-induced Nausea and Vomitting Treatment market's momentum in the near term.

5. Which regions lead the market and why?

North America remains the leader, accounting for over 40% of revenue, due to robust oncology infrastructure and favorable reimbursement. Europe follows, while Asia‑Pacific shows the fastest CAGR, propelled by expanding cancer care networks and rising patient awareness.

6. Who are the top companies competing in this space?

Leading players include Astellas Pharma, Merck & Co., Eisai Co., and Helsinn Group, each offering NK‑1 antagonists or 5‑HT₃ blockers. Smaller innovators such as OncoPharm and Zymeworks focus on novel oral formulations and combination therapies in the market.

7. What future opportunities are emerging for market participants?

Future opportunities involve personalized anti‑emetic regimens based on pharmacogenomics, integration of digital adherence monitoring, and expansion into emerging economies where chemotherapy rates are climbing. Companies that secure patents on next‑generation NK‑1 inhibitors can capture premium market share.

8. How is technology influencing treatment development?

Advanced drug‑delivery platforms, such as liposomal encapsulation and transdermal patches, improve bioavailability and reduce side effects. AI‑driven target discovery accelerates identification of novel receptors, while telehealth platforms enable real‑time nausea management, reshaping the Chemotheraphy-induced Nausea and Vomitting Treatment market.

9. What is the regulatory landscape for these therapies?

Regulators in major markets require rigorous Phase III trials demonstrating both efficacy and safety for anti‑emetic agents. The FDA’s Fast Track designation and EMA’s PRIME scheme expedite review for innovative NK‑1 antagonists, influencing the market’s future outlook.

Contact for Full Report

Loading report content...

Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends & Competitive Analysis 2033

Market Snapshot

Chemotheraphy-induced Nausea and Vomitting Treatment Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Chemotheraphy-induced Nausea and Vomitting Treatment Segmentation

Chemotheraphy-induced Nausea and Vomitting Treatment Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Chemotheraphy-induced Nausea and Vomitting Treatment market size?

2. What is the forecasted growth rate and market outlook through 2032?

3. What are the primary drivers fueling market expansion?

4. What challenges could hinder market growth?

5. Which regions lead the market and why?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for market participants?

8. How is technology influencing treatment development?

9. What is the regulatory landscape for these therapies?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Chemotheraphy-induced Nausea and Vomitting Treatment Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Chemotheraphy-induced Nausea and Vomitting Treatment Segmentation

Chemotheraphy-induced Nausea and Vomitting Treatment Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Chemotheraphy-induced Nausea and Vomitting Treatment market size?

2. What is the forecasted growth rate and market outlook through 2032?

3. What are the primary drivers fueling market expansion?

4. What challenges could hinder market growth?

5. Which regions lead the market and why?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for market participants?

8. How is technology influencing treatment development?

9. What is the regulatory landscape for these therapies?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation